aacr 2023 abstract search

December 811, 2020; San Antonio, TX, Abstracts: AACR Special Conference on Modernizing Population Sciences in the Digital Age November 25, 2018; New Orleans, LA, Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we have listed in the below table. What Is the Utility of PDX and Organoid Models in the Era of Immuno-oncology. May 1821, 2014; New Orleans, LA, Abstracts: AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy AACR Annual Meeting 2023 - Simultaneous Publication: Frequently Asked Questions Which manuscripts qualify for the simultaneous publication opportunity? Strategic Importance of Portfolio Management in the Pharma and Healthcare Industry, Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment, patients with hepatocellular carcinoma (HCC), patients with HR+/ HER2- advanced breast cancer, platinum-based chemotherapy in locally advanced or metastatic EGFR-mutated NSCLC, patients with CD30-positive relapsed or refractory PTCL, recurrent/metastatic (R/M) HPV-16 positive anogenital cancers, IMbrave050: Phase III study of adjuvant atezolizumab + bevacizumab versus active surveillance in, HCC at High Risk of Recurrence After Surgical Resection or Ablation (Adjuvant), AEGEAN: Phase III trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC, Stages II and III NSCLC (Neoadjuvant/Adjuvant), KEYNOTE-966: Pembrolizumab in combination with gemcitabine and cisplatin for advanced biliary tract cancer a Phase III study, Advanced and/or Unresectable Biliary Tract Carcinoma (1L), ACTION: Phase III study of dordaviprone (ONC201) in patients with newly diagnosed H3 K27M-mutant diffuse glioma, H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy (1L), Optune + Radiation therapy + Temozolomide (*Optune is a device), TRIDENT: Phase III study (EF-32): First-line Tumor Treating Fields (TTFields; 200 kHz) therapy concomitant with chemo-radiation, followed by maintenance TTFields/temozolomide in newly diagnosed glioblastoma, VIKTORIA-1: Phase III study of gedatolisib + fulvestrant palbociclib in, Patients With HR+/HER2- Advanced Breast Cancer (2L), Flamingo-01: Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, HER2/Neu + Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy, HERTHENA-Lung02: A randomized Phase III study of patritumab deruxtecan vs, Metastatic or Locally Advanced EGFRm NSCLC after failure of EGFR Tyrosine Kinase Inhibitor therapy (2L+), Encorafenib + binimetinib + pembrolizumab, STARBOARD: Phase III study evaluating encorafenib + binimetinib + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma, Unresectable Locally Advanced or Metastatic BRAF V600-mutant Melanoma (1L), Keynote-942 : A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from open-label Phase II mRNA-4157-P201, Relapsed or Refractory CD30-positive PTCL (2L), Phase II trial of TG4001 plus avelumab versus avelumab alone in, Patients With HPV-16 Positive Recurrent or Metastatic Malignancies (2L), Pembrolizumab + Standard of Care (SOC) MK-4830, MK-4830-002: Phase II study of pembrolizumab + chemotherapy MK-4830 as neoadjuvant treatment for high-grade serous ovarian cancer, Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer, Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression < 1% or a PD-L1 Expression 1% and an STK11 Co-mutation (1L), PRECISION I: Phase II, multicenter open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2, Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes, Phase II study of savolitinib in patients with METamplified gastroesophogeal junctio (GE) n adenocarcinomas or gastric cancer, Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications (2L), Cinrebafusp alfa + ramucirumab + paclitaxel, Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in, innovaTV 207: Tisotumab vedotin in squamous cell carcinoma of head and neck (SCCHN): interim analysis from Phase II. September 2528, 2017; Atlanta, GA, Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy areas February 811, 2015; San Francisco, CA, Abstracts: AACR-SNMMI Joint Conference: State-of-the-Art Molecular Imaging in Cancer Biology and Therapy Cancer Researchers / Other Health Care Professionals, AACR Annual Meeting 2023: News and Highlights, AACR Scientific Achievement Awards, Lectureships, and Prizes, myAACR Support: Virtual Meeting Access / Registration, Scholar-in-Training Awards: Annual Meeting, AACR Minority Scholar in Cancer Research Awards, AACR Minority and Minority-serving Institution Faculty Scholar in Cancer Research Awards, AACR Scholar-in-Training Awards: Other Conferences and Meetings, AACR Statement Regarding Venues for the AACR Annual Meeting and Other Conferences, Advances in the Science of Cancer Health Disparities. February 1114, 2016; New Orleans, LA, Abstracts: AACR Precision Medicine Series: Cancer Cell Cycle - Tumor Progression and Therapeutic Response December 812, 2010; San Antonio, TX, Abstracts: AACR International Conference: The Science of Cancer Health Disparities April 1620, 2016; New Orleans, LA, Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care Copyright 2023 by the American Association for Cancer Research. Philadelphia, PA 19106-4404 USA You will also see an Open in iBooks button in the top right. June 1821, 2012; Lake Tahoe, NV, Abstracts: Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research June 1821, 2014; Orlando, FL, Abstracts: 10th Biennial Ovarian Cancer Research Symposium 2008 | October 2630, 2017; Philadelphia, PA, Abstracts: AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research April 46, 2023, Proceedings: AACR Annual Meeting 2023; April 14-19, 2023; Orlando, FL; Part 1 (Regular and Invited Abstracts) Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. December 69, 2013; Atlanta, GA, Abstracts: AACR IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine 2007 | November 1618, 2008; National Harbor, MD, Abstracts: Thirty-First CTRC-AACR San Antonio Breast Cancer Symposium Poster presentations are to be fully in-person at the meeting. September 2528, 2016; New York, NY, Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy April 1721, 2010; Washington, DC, Abstracts: AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development Download the .mobi files from the links below. Benchmarking, Portfolio December 48, 2012; San Antonio, TX, Proceedings: AACR 102nd Annual Meeting 2011 January 710, 2015; La Jolla, CA, Abstracts: AACR Special Conference: Translation of the Cancer Genome Once the file has downloaded it will open automatically in iBooks. October 1619, 2012; Anaheim, CA, Abstracts: Fifth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved April 15, 2006; Washington DC, Abstracts: First AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development; Sep 1215, 2006, Abstracts: Fifth AACR International Conference on Frontiers in Cancer Prevention Research In the control panel window, select the appearance and personalization link. Other AACR 2023 abstracts of note Selected oral presentations are listed below. 2023 AACR Special Conference: Ovarian Cancer. Select "Patients / Caregivers / Public" or "Researchers / Professionals" to filter your results. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment. December 25, 2017; Orlando, FL, Abstracts: AACR Special Conference: Pediatric Cancer Research: From Basic Science to the Clinic How are Nanobots Proving Their Excellence in the Healthcare Industry? October 2225, 2011; Boston, MA, Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (HCC), according to research presented at the AACR Annual Meeting 2023. . If you already have an iBooks entry, the documents will appear there. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we have listed in the below table. H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. December 610, 2022, Abstracts: AACR Virtual Special Conference: The Evolving Tumor Microenvironment in Cancer Progression: Mechanisms and Emerging Therapeutic Opportunities; in association with the Tumor Microenvironment (TME) Working Group Headlines; Drugs; . 2022 | May 912, 2012; San Diego, CA, Abstracts: AACR Special Conference on Chemical Systems Biology: Assembling and Interrogating Computational Models of the Cancer Cell by Chemical Perturbations Which Countries Top the Chart in Global Pharmaceutical Market? If you prefer, you can also download the .epub files to your PC, mount your Samsung devices SD card, and copy the files to the SD card from your computer so that they will open directly in the reader app. The investigational drug VT3989 appears safe and can produce responses in patients with refractory mesothelioma or sarcoma, according to a study presented at the AACR Annual Meeting 2023. In. If it doesnt, select Open with Kindle. Methods Retrospective review of prospectively collected endovascular databases in four comprehensive stroke centers, including . September 1720, 2007; Atlanta, GA, Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics 2023 American Association for Cancer Research September 30Oct 3, 2010; Miami, FL, Abstracts: Ninth Annual AACR International Conference on Frontiers in Cancer Prevention Research Assessment, Regulatory In the advance settings options, uncheck the hide extensions for known file types box (8th check box listed). 2016 | ET) Pemigatinib Drug Combination Screen Identifies Pemigatinib, an FGFR Inhibitor, as a Mechanism to Overcome KRASG12C. March 58, 2023; Philadelphia, PA, Abstracts: AACR Special Conference: Advances in Prostate Cancer Research Attention here could fall on Vivace Therapeutics' YAP/TEAD inhibitor VT3989, which has an AACR oral presentation of first-in-human data. For the first poster, we developed a prostate cancer PDX model radioresistant to PSMA targeted radionuclide therapy. Berlin, April 11, 2023 - Bayer will present latest research across its oncology portfolio at the American Association for Cancer Research (AACR) 2023 Annual Meeting Bayer is progressing novel research around its prostate cancer treatment darolutamide. September 1316, 2022; Boston, MA, Abstracts: 15th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved TABLE OF CONTENTS 3 AACR Annual Meeting 2023 Ky Dae est 5 Welcome 6 Why You Should Aendt t 7 Program 11 Spotlight on Clinical Trials 12 Professional Advancement Opportunities 14 Exhibit Show 15 Continuing Medical Education (CME) 16 AACR Scient tis Survivor Program 17 Press Cerovage and Social Media 18 Financial Support for Attendance 20 Guidelines for Prepartion and a Telephone: 215-440-9300 January 1114, 2020; San Diego, CA, Abstracts: AACR Special Conference on Advances in Liquid Biopsies Individuals planning on presenting an abstract at this conference are encouraged to register and make a room reservation at the conference hotel as early as possible. February 26March 1, 2014; San Diego, CA, Proceedings: AACR 105th Annual Meeting 2014 AbstractPurpose:. Submit your late-breaking and clinical trials abstract from December 16 through January 12 for. Here, we performed an explorative . September 1417, 2014; Philadelphia, PA, Abstracts: AACR Special Conference on Advances in Melanoma: From Biology to Therapy a leading forum for scientists and engineers to exchange. Emerging evidence suggests that not only the frequency and composition of tumor-infiltrating leukocytes but also their spatial organization might be a major determinant of tumor progression and response to therapy. The findings will be relevant not only for Vivace, a little-known private biotech, but also for Ikena Oncology, whose TEAD inhibitor IK-930 entered phase 1 last year. Home > Cancer Researchers / Other Health Care Professionals > Meetings > Meetings and Workshops Calendar > AACR Annual Meeting 2023 > Key Dates, 615 Chestnut St., 17th Floor May 1720, 2013; Bellevue, WA, Abstracts: AACR Special Conference on Chromatin and Epigenetics in Cancer This research investigates the association between benzodiazepines (BZD) and cancer patient survival outcomes, the pancreatic cancer tumor microenvironment, and cancer-associated fibroblast (CAF) signaling.Experimental Design:. If not, go to My Computer and you should find the Kindle there. April 610, 2013; Washington, DC, Abstracts: AACR Precision Medicine Series: Synthetic Lethal Approaches to Cancer Vulnerabilities June 2427, 2023; Austin, TX, Abstracts: AACR Special Conference: Evolutionary Dynamics in Carcinogenesis and Response to Therapy November 59, 2015; Boston, MA, Abstracts: AACR Special Conference: Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship Several CCR scientists will present their research at the AACR Annual Meeting in Orlando between April 14-19, 2023. Home > Cancer Researchers / Other Health Care Professionals > Meetings > Meetings and Workshops Calendar > AACR Annual Meeting 2023 > Program. solutions for life science vertical and offering quintessential advisory services in the Abstracts are no longer being accepted for this conference. The table includes information about ongoing clinical trials for cancer drugs and devices, which various pharma companies are conducting in the high and mid stages of development. June 2224, 2019; Charlotte, NC, Abstracts: AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care To further refine your search, toggle appropriate sections on or off. Although the clinical efficacy of pan-FGFR inhibitors (pan-FGFRi) validates FGFR2 driver status in FGFR2 fusion-positive intrahepatic cholangiocarcinoma, their benefit is limited by . Tap this button. 2017 | 2010 | How to Cite Abstracts | CME Information | Other AACR Meetings, 2023 | January 1314, 2021, Abstracts: AACR Virtual Meeting: COVID-19 and Cancer November 30December 3, 2015; Boston, MA, Abstracts: AACR Special Conference: Noncoding RNAs and Cancer: Mechanisms to Medicines To further refine your search, toggle appropriate sections on or off. October 2630, 2019; Boston, MA, Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy September 1619, 2015; New York, NY, Abstracts: AACR Special Conference: Chromatin and Epigenetics in Cancer Copy the file you downloaded into the My Documents folder. If an abstract is not accepted for presentation at the conference, the presenter may request a full refund of the registration fee. For programs that include proffered talks selected from the abstract submissions, instructions will be sent to the ABSTRACT PRESENTERS with the date, time, and format for those presentations. May 1215, 2016; Orlando, FL, Abstracts: AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer This website uses cookies to ensure the best user experience. April 1419, 2023; Orlando, FL, Abstracts: AACR Special Conference: Advances in Kidney Cancer Research Select the folder options link, and click the view tab at the top of the folder options window. Click the Market icon on your Android and search for eBook readers such as Aldiko Book Reader, Google Books, Kobo eBook Reader, Nook for Android, etc. The files will display as titles in your Catalog. Assessment, Market January 1822, 2017; Cape Town, South Africa, Proceedings: AACR Annual Meeting 2017 December 69, 2009; Houston, TX, Abstracts: Thirty-Second Annual CTRC-AACR San Antonio Breast Cancer Symposium Development, Competitive April 14-19, 2023. Once an abstract has been submitted, it may be withdrawn only by written request from the ABSTRACT PRESENTER. December 610, 2016; San Antonio, TX, Abstracts: AACR Special Conference: Myc: From Biology to Therapy January 2325, 2023; Austin, TX, Abstracts: AACR Special Conference: Targeting RAS September 69, 2019; Boston, MA, Abstracts: AACR Special Conference on Advances in Ovarian Cancer Research Email: [emailprotected], Cancer Researchers / Other Health Care Professionals, Eliminating Racial Inequities in Cancer Research, CRI-ENCI-AACR International Cancer Immunotherapy Conference, AACR Conference on the Science of Cancer Health Disparities, Molecular Targets and Cancer Therapeutics, ASCO/AACR Methods in Clinical Cancer Research, Translational Cancer Research for Basic Scientists, Design and Implementation of Clinical Trials, Eliminating Racial Inequities In Cancer Research, Scientific Achievement Awards and Lectureships, Science Policy and Government Affairs Committee, The AACR June L. Biedler Prize for Cancer Journalism, 1916-1939: Focus on Knowledge Dissemination, 1940-1963: Rapid Growth of Research and the AACR, 1964-1981: Emerging Leadership in the Cancer Community, 2000-Present: At the Forefront of Cancer Science in the 21st Century, Blog: AACR Celebrates 115 Years as the Driving Force to Eradicate Cancer, Landmarks in Cancer Research: 2011-Present, Cancer Researchers / Other Health Care Professionals, AACR Special Conference in Cancer Research: Advances in Breast Cancer Research, myAACR Support: Virtual Meeting Access / Registration, Scholar-in-Training Awards: Annual Meeting, AACR Minority Scholar in Cancer Research Awards, AACR Minority and Minority-serving Institution Faculty Scholar in Cancer Research Awards, AACR Scholar-in-Training Awards: Other Conferences and Meetings, AACR Statement Regarding Venues for the AACR Annual Meeting and Other Conferences. Abstracts are no longer being accepted for this conference. And while we often think of these microbes as something to avoid (hand sanitizer, anyone? September 30October 3, 2018; New York, NY, Abstracts: Eleventh AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved 2023 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethic Minorities and the Medically Underserved. Select rename and change the .zip extension to .epub. November 912, 2015; Fort Lauderdale, FL, Abstracts: Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved June 1316, 2015; Salt Lake City, UT, Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival Therefore, mapping and analyzing the fine tumor immune architecture could potentially provide insights for predicting cancer prognosis. September 79, 2022, Abstracts: AACR Special Conference: Rethinking DCIS: An Opportunity for Prevention? September 2427, 2017; Orlando, Florida, Abstracts: Tenth AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved February 2427, 2014; Lake Buena Vista, FL, Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment Users can search and browse invited speaker sessions and proffered paper sessions through the online program planner. Now for An Evening With City of Hope. AACR 2023 - more hope for Moderna's neoantigen immunotherapy Jacob Plieth After Moderna/Merck & Co's December splash, full data from Keynote-942 stand up to scrutiny. February 36, 2009; Carefree, AZ, Proceedings: AACR 100th Annual Meeting 2009 January 811, 2018; San Diego, CA, Proceedings: AACR Annual Meeting 2018 How Can We Improve Workforce Recruitment and Retention? CCR presentations at AACR 2023. July 2023, 2008; Monterey, CA, Abstracts: AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development You should then see a new entry for the eBook in the menu on your Kindle. Cr avec Wix.com. September 1720, 2016; Tampa, FL, Abstracts: Ninth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved February 35, 2021, Abstracts: AACR Virtual Special Conference on Radiation Science and Medicine May 1821, 2019; Denver, CO, Abstracts: AACR Special Conference on Environmental Carcinogenesis: Potential Pathway to Cancer Prevention Additionally, oral presentations of highly rated abstracts will be integrated within thematic sessions. Philadelphia, PA 19106-4404 USA 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics. Please Note: Make sure you are using the Light Classic font to ensure that the content renders correctly. 2014 | June 2326, 2022; Boston, MA, Abstracts: Second Biennial NCI Meeting: Translational Advances in Cancer Prevention Agent Development (TACPAD) The agenda of this preview includes a quick glance at the top company-sponsored abstracts expected to present their much-awaited data readouts, while a few of them are all set to present their prospective trial designs. 2005 | AACR 2023. Management, Pipeline New for 2023! The consultation ran from 23 March 2023 to 13 April 2023. September 1718, 2020, Abstracts: AACR Virtual Special Conference on Pancreatic Cancer 2022 Meetings Abstracts: AACR Special Conference: Evolutionary Dynamics in Carcinogenesis and Response to Therapy March 14-17, 2022 Proceedings: AACR Annual Meeting 2022 April 8-13, 2022; New Orleans, LA Proceedings: AACR Annual Meeting 2023; April 14-19, 2023; Orlando, FL; Part 1 (Regular and Invited Abstracts) April 14-19, 2022; Orlando, FL Clinical trial and late-breaking abstracts (submitted for the January 12, 2023 deadline) that were presented at the AACR Annual Meeting are only available in PDF format. December 1014, 2019; San Antonio, TX, Abstracts: Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic September 1315, 2018; Seattle, WA, Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival 1 April 2023 Abstract Poster Presentations - Proffered Abstracts | April 04 2023 Abstract 502: ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy Yangguang Li; Jianping Wu; Jinxin Liu; Luoheng Qin; Xin Cai; Junwen Qiao; Ling Wang; Sujata Rao; Feng Ren; Alex Zhavoronkov Author & Article Information LUMINOSITY: Preliminary efficacy of telisotuzumab vedotin treatment in the 2L/3L setting in MET gene amplified (MET Amp), c-Met protein overexpressing (c-Met OE), c-Met+ Non-Small Cell Lung Cancer (2L/3L), A first-in-human Phase I study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12Cmutant advanced solid tumors, Phase Ib study of GDC-6036 in combination with cetuximab in patients with colorectal cancer (CRC) with KRAS G12C mutation, Colorectal cancer with KRAS G12C mutation, Phase I study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors: Updated results of the phase I study, Advanced Solid Tumors With KRAS G12C Mutations, A first-in-human, Phase Ia/Ib, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors, Trials in progress: a global Phase I/Ib clinical trial evaluating exarafenib (KIN-2787), a highly selective pan-RAF inhibitor, in adult patients with BRAF-altered solid tumors and NRAS mutant melanoma, BRAF/NRAS-mutated advanced or Metastatic Solid tumors, BGB-283 (lifirafenib) + PD-0325901 (mirdametinib), Safety, pharmacokinetics, and antitumor activity findings from a Phase Ib, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors, Patients With Advanced or Refractory Solid Tumors, Sacituzumab govitecan + zimberelimab + etrumadenant, VELOCITY-Lung: A phase II study evaluating safety and efficacy of sacituzumab govitecan + zimberelimab + etrumadenant in patients with advanced or metastatic non-small cell lung cancer (mNSCLC) progressing on or after platinum (PT)- based chemotherapy and checkpoint inhibitors (CPI), Imvotamab + ZYNLONTA (loncastuximab tesirine), A phase I/II randomized study of imvotamab monotherapy and in combination with loncastuximab tesirine in relapsed/refractory non-Hodgkin lymphomas, Datopotamab deruxtecan Anticancer Agents, TROPION-PanTumor03: Phase II, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumors, Pembrolizumab with and without sacituzumab govitecan as first line treatment for metastatic non-small-cell lung cancer (NSCLC) with PD-L1 TPS 50%: phase III KEYNOTE-D46/EVOKE-03 study, Participants With PD L1 TPS Greater Than or Equal to 50% mNSCLC (1L), Double-blind placebo-controlled trial of AL102 for, Patients With Progressing Desmoid Tumors (1L+ , 2L+), Data presentation by Key pharma players such as, Drawing attention to the Phase II data readout, we have cancer vaccine players.

Owyhee County Landfill, Articles A